Sichenzia Ross Ference Kesner LLP Represents Tonix Pharmaceuticals in $5.2 Million Public Offering
Press Release – New York, NY – November 1, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it represented Tonix Pharmaceuticals Holding Corp. (NASDAQ “TNXP”), a developer of next-generation medicines for common disorders of the central nervous system, with its lead program focusing on post traumatic stress disorder, in an underwritten public offering of 9,500,000 units, with each unit consisting of one (1) share of common stock and a warrant to purchase one-half (0.5) of a share of common stock. The Units were sold at a public offering price of $0.55 per Unit, for aggregate gross proceeds of $5.2 million. Dawson James Securities, Inc. acted as the sole book-running manager for the offering.
The Sichenzia Ross Ference Kesner LLP team was led by partners Marc J. Ross and James M. Turner and associate S. Ashley Jaber.
- Sichenzia Ross Ference Carmel LLP represents Madison Global Partners, LLC in an Unsecured Senior Convertible Note and Warrant Offering up to $1 Million - December 6, 2024
- Sichenzia Ross Ference Carmel LLP Represents D. Boral Capital in $1.7 Million Registered Direct Offering of SRM Entertainment - December 5, 2024
- Sichenzia Ross Ference Carmel LLP Represents A.G.P/Alliance Global Partners in $8 Million Private Placement of TransCode Therapeutics - December 4, 2024